The Council of Ministers has endorsed two regulations that will enhance the country’s efforts towards developing local vaccine manufacturing capacity
Developing local vaccine manufacturing capacity is one of Government of Ethiopia’s priorities and the Ministry of Health is working with various stakeholders to achieve this goal.
Today, is a huge milestone for this initiative as the Council of Minister’s has endorsed the regulations for the establishment of ShieldVax Enterprise which is being established for the manufacturing of human vaccines and other biological, as well as the regulation for the establishment of Ethio-BioPharma Group, an umbrella enterprise that will include the existing National Veterinary Institute (NVI) known for its long service in veterinary vaccine manufacturing and the newly established ShieldVax Enterprise. The group will manufacture essential medical products (vaccines, pharmaceuticals, medical supplies and diagnostics) for both humans and animals for local and global markets.
This is a big step forward to ensure the national health security through improving sustainable and quality assured access to essential medical products. It lays strong foundation to ensure the country’s emergency preparedness and resilient healthcare system. Furthermore, it will help the advancement of manufacturing technologies, knowledge and skill in human and animal health, while it also has economic impact in line with our strategy for import substitution, enhancing export and improving job creation in the sector.
The establishment of the group and the enterprise is timely to build national capacity and is in line with Africa Union’s ambitious plan to produce 60% of human vaccine that Africa needs by 2040 within the continent. It also enhances Ethiopia’s capacity to contribute for the on-going global efforts in the eradication of rabies and PPR, important animal diseases impacting the lives and livelihoods of billions of people worldwid.
The council of ministers has approved two regulations that will enable to create the capacity of domestic vaccine production.
___
Building the production capacity of local vaccine is one of the focus of the government. The Ministry of Health is working with various stakeholders to achieve this.
Even today, the Council of Ministers has approved the rules for establishing the ShieldVax enterprise and the proposed National Animal Health Institute (NVI). The group is formed including the National Institute of Animal Health that has 60 years of experience (vaccines, pharmaceuticals, medical devices and tests) that are essential for both human and animal health, both domestic and international. Countries will be a marketer.
The approval of the regulations is a big step in protecting the health of the nation by making these essential products sustainable and quality guaranteed and improving their availability. This lays the foundation for ensuring the country’s emergency preparedness and creating a strong health care system. In addition, the establishment of the group is in line with our strategy to increase the transfer of manufacturing technology knowledge and skills in order to increase human and animal health and to replace imported products locally and strengthen export capacity and create job opportunities in the sector.
The establishment of this group and enterprise is in line with the African Union’s plan to produce 60% of the vaccines Africa needs by 2040. It will also help to create capacity in the animal health sector to support the campaign to eradicate rabies and small invasive diseases.
The Council of Ministers has endorsed two regulations that will enhance the country’s efforts towards developing local vaccine manufacturing capacity
_
Developing local vaccine manufacturing capacity is one of Government of Ethiopia’s priorities and the Ministry of Health is working with various stakeholders to achieve this goal.
Today, is a huge milestone for this initiative as the Council of Minister’s has endorsed the regulations for the establishment of ShieldVax Enterprise which is being established for the manufacturing of human vaccines and other biological, as well as the regulation for the establishment of Ethio-BioPharma Group, an umbrella enterprise that will include the existing National Veterinary Institute (NVI) known for its long service in veterinary vaccine manufacturing and the newly established ShieldVax Enterprise. The group will manufacture essential medical products (vaccines, pharmaceuticals, medical supplies and diagnostics) for both humans and animals for local and global markets.
This is a big step forward to ensure the national health security through improving sustainable and quality assured access to essential medical products. It lays strong foundation to ensure the country’s emergency preparedness and resilient healthcare system. Furthermore, it will help the advancement of manufacturing technologies, knowledge and skill in human and animal health, while it also has economic impact in line with our strategy for import substitution, enhancing export and improving job creation in the sector.
The establishment of the group and the enterprise is timely to build national capacity and is in line with Africa Union’s ambitious plan to produce 60% of human vaccine that Africa needs by 2040 within the continent. It also enhances Ethiopia’s capacity to contribute for the on-going global efforts in the eradication of rabies and PPR, important animal diseases impacting the lives and livelihoods of billions of people worldwide.